Gloria Brunori1,2,3, Michelle Weger2, Jennifer Schoch1,2, Katarzyna Targowska-Duda1,4, Megan Barnes1, Anna Maria Borruto3, Linda M Rorick-Kehn5, Nurulain T Zaveri6, John E Pintar7, Roberto Ciccocioppo3, Lawrence Toll1,2, Andrea Cippitelli1,2. 1. Department of Biomedical Science, Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, Florida. 2. Torrey Pines Institute for Molecular Studies, Port St. Lucie, Florida. 3. Pharmacology Unit, School of Pharmacy, University of Camerino, Camerino, Italy. 4. Department of Biopharmacy, Medical University of Lublin, Lublin, Poland. 5. Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana. 6. Astraea Therapeutics Inc., Mountain View, California. 7. Department of Neuroscience and Cell Biology, Rutgers Robert Wood Johnson Medical School, Piscataway, New Jersey.
Abstract
BACKGROUND: The nociceptin/orphanin FQ opioid peptide (NOP) receptor and its endogenous ligand N/OFQ have been implicated in the regulation of drug and alcohol use disorders (AUD). In particular, evidence demonstrated that NOP receptor activation blocks reinforcing and motivating effects of alcohol across a range of behavioral measures, including alcohol intake, conditioned place preference, and vulnerability to relapse. METHODS: Here, we show the effects of pharmacological activation and inhibition of NOP receptors on binge-like alcohol consumption, as measured by the "drinking in the dark" (DID) model in C57BL/6J mice. RESULTS: We found that 2 potent and selective NOP agonists AT-202 (0, 0.3, 1, 3 mg/kg) and AT-312 (0, 0.3, 1 mg/kg) did not affect binge alcohol drinking at doses that do not affect locomotor activity. AT-202 also failed to alter DID behavior when administered to mice previously exposed to chronic alcohol treatment with an alcohol-containing liquid diet. Conversely, treatment with either the high affinity NOP receptor antagonist SB-612111 (0, 3, 10, 30 mg/kg) or the selective antagonist LY2817412 (0, 3, 10, 30 mg/kg) decreased binge drinking. SB-612111 was effective at all doses examined, and LY2817412 was effective at 30 mg/kg. Consistently, NOP receptor knockout mice consumed less alcohol compared to wild type. SB-612111 reduced DID and increased sucrose consumption at doses that do not appear to affect locomotor activity. However, the high dose of SB-612111 (30 mg/kg) reduced alcohol intake but failed to inhibit preference in a 2-bottle choice DID model that can assess moderate alcohol intake. CONCLUSIONS: The present results suggest that NOP receptor inhibition rather than activation may represent a valuable approach for treatment of AUD characterized by excessive alcohol consumption such as binge drinking.
BACKGROUND: The nociceptin/orphanin FQ opioid peptide (NOP) receptor and its endogenous ligand N/OFQ have been implicated in the regulation of drug and alcohol use disorders (AUD). In particular, evidence demonstrated that NOP receptor activation blocks reinforcing and motivating effects of alcohol across a range of behavioral measures, including alcohol intake, conditioned place preference, and vulnerability to relapse. METHODS: Here, we show the effects of pharmacological activation and inhibition of NOP receptors on binge-like alcohol consumption, as measured by the "drinking in the dark" (DID) model in C57BL/6J mice. RESULTS: We found that 2 potent and selective NOP agonists AT-202 (0, 0.3, 1, 3 mg/kg) and AT-312 (0, 0.3, 1 mg/kg) did not affect binge alcohol drinking at doses that do not affect locomotor activity. AT-202 also failed to alter DID behavior when administered to mice previously exposed to chronic alcohol treatment with an alcohol-containing liquid diet. Conversely, treatment with either the high affinity NOP receptor antagonist SB-612111 (0, 3, 10, 30 mg/kg) or the selective antagonist LY2817412 (0, 3, 10, 30 mg/kg) decreased binge drinking. SB-612111 was effective at all doses examined, and LY2817412 was effective at 30 mg/kg. Consistently, NOP receptor knockout mice consumed less alcohol compared to wild type. SB-612111 reduced DID and increased sucrose consumption at doses that do not appear to affect locomotor activity. However, the high dose of SB-612111 (30 mg/kg) reduced alcohol intake but failed to inhibit preference in a 2-bottle choice DID model that can assess moderate alcohol intake. CONCLUSIONS: The present results suggest that NOP receptor inhibition rather than activation may represent a valuable approach for treatment of AUD characterized by excessive alcohol consumption such as binge drinking.
Authors: J Andrew Hardaway; Lindsay R Halladay; Christopher M Mazzone; Dipanwita Pati; Daniel W Bloodgood; Michelle Kim; Jennifer Jensen; Jeffrey F DiBerto; Kristen M Boyt; Ami Shiddapur; Ava Erfani; Olivia J Hon; Sofia Neira; Christina M Stanhope; Jonathan A Sugam; Michael P Saddoris; Greg Tipton; Zoe McElligott; Thomas C Jhou; Garret D Stuber; Michael R Bruchas; Cynthia M Bulik; Andrew Holmes; Thomas L Kash Journal: Neuron Date: 2019-04-24 Impact factor: 17.173
Authors: Rachel I Anderson; Marcelo F Lopez; William C Griffin; Harold L Haun; Daniel W Bloodgood; Dipanwita Pati; Kristen M Boyt; Thomas L Kash; Howard C Becker Journal: Neuropsychopharmacology Date: 2018-12-11 Impact factor: 7.853
Authors: Paola F Zaratin; Giuseppe Petrone; Massimo Sbacchi; Martine Garnier; Claudia Fossati; Paola Petrillo; Silvio Ronzoni; Giuseppe A M Giardina; Mark A Scheideler Journal: J Pharmacol Exp Ther Date: 2003-10-30 Impact factor: 4.030
Authors: J Andrew Hardaway; Jennifer Jensen; Michelle Kim; Christopher M Mazzone; Jonathan A Sugam; Jeffrey F Diberto; Emily G Lowery-Gionta; Lara S Hwa; Kristen E Pleil; Cynthia M Bulik; Thomas L Kash Journal: Behav Brain Res Date: 2016-03-29 Impact factor: 3.332
Authors: J C Meunier; C Mollereau; L Toll; C Suaudeau; C Moisand; P Alvinerie; J L Butour; J C Guillemot; P Ferrara; B Monsarrat Journal: Nature Date: 1995-10-12 Impact factor: 49.962